List view / Grid view
8 November 2018 | By Iqra Farooq (European Pharmaceutical Review)
A review of a study on children with liver cancer has shown the effectiveness of Transarterial Radioembolization with Yttrium-90 as a course of treatment...
29 August 2018 | By Peak Scientific
Modern laboratories use a number of gases as part of their daily operations. This application note details two of the most common methods of laboratory gas supply, and their associated safety risks and benefits...
8 August 2018 | By Mike Stones
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
6 August 2018 | By Mike Stones
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
5 June 2018 | By Dr Zara Kassam (European Pharmaceutical Review), zae
Once-daily oral pill could replace preoperative chemotherapy in patient population if validated in larger trials...
30 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Protein inhibits inflammatory response underlying chronic pain processing may provide an alternative to opioids for severe, persistent pain...
20 April 2018 | By European Pharmaceutical Review
A new non-toxic method for delivering anti-cancer drugs to specific parts of the human body could mean the end of the severe side effects...
6 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
11 December 2017 | By Steve Bremer (European Pharmaceutical Review)
With access challenges even after successful but costly development programmes, the industry is under pressure to speed up the clinical development process and produce more for less. Adaptive trial designs, more collaborative working and data sharing could provide a solution in the area of cancer immunotherapy, says Jacqueline Karmel, principal…
5 December 2017 | By European Pharmaceutical Review
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
9 November 2017 | By European Pharmaceutical Review
A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells.
18 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
6 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
14 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
4 May 2017 | By Niamh Marriott, Junior Editor
The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML...
Follow: